ESC 365 - Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial

Open Access

Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial

Session: Beating the odds: advances in cardiac amyloidosis treatment

Topic: Clinical

Speaker: Assistant Professor K. Alexander (Palo Alto, US)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Assistant Professor Kevin Alexander

Stanford University School of Medicine, Palo Alto (United States of America)

0 follower

6 more presentations in this session

Cause of death in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): findings from the ATTRibute-CM study

Speaker: Doctor L. Obici (Pavia, IT)

Effect of acoramidis on functional capacity and quality of life in patients with variant ATTR-CM: results from ATTRibute-CM

Speaker: Professor M. Fontana (London, GB)

Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM

Speaker: Professor M. Fontana (London, GB)

Bioactive adrenomedullin as a predictor of clinical outcomes in cardiac transthyretin amyloidosis

Speaker: Mr M. Mueller (Berlin, DE)

Neurohormonal therapies at baseline and follow-up and survival in patients with wild-type transthyretin cardiac amyloidosis

Speaker: Doctor A. Aimo (Pisa, IT)

Access the full session

Beating the odds: advances in cardiac amyloidosis treatment

Speakers: Assistant Professor K. Alexander, Doctor L. Obici, Professor M. Fontana, Professor M. Fontana, Mr M. Mueller...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources